Entrada Therapeutics Inc (TRDA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 22.83 is considered Overvalued compared with the five-year average of -15.69. The fair price of Entrada Therapeutics Inc (TRDA) is between 1.78 to 7.11 according to relative valuation method. Compared to the current price of 12.12 USD , Entrada Therapeutics Inc By Overvalued By 70.39%.

Relative Value

Fair Zone

1.78-7.11

Current Price：12.12

70.39%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Entrada Therapeutics Inc (TRDA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Entrada Therapeutics Inc (TRDA) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.48, the current P/B ratio is approximately -28.49% higher. Relative to its 5-year average P/B ratio of 1.41, the current P/B ratio is about -25.19% higher. Entrada Therapeutics Inc (TRDA) has a Forward Free Cash Flow (FCF) yield of approximately -36.01%. Compared to its 3-year average FCF yield of -5.72%, the current FCF yield is approximately 530.08% lower. Relative to its 5-year average FCF yield of -10.17%, the current FCF yield is about 253.96% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TRDA competitors is 11.22, providing a benchmark for relative valuation. Entrada Therapeutics Inc Corp (TRDA.O) exhibits a P/S ratio of 22.83, which is 103.53% above the industry average. Given its robust revenue growth of -96.53%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TRDA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TRDA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TRDA currently overvalued or undervalued?

Entrada Therapeutics Inc (TRDA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 22.83 is considered Overvalued compared with the five-year average of -15.69. The fair price of Entrada Therapeutics Inc (TRDA) is between 1.78 to 7.11 according to relative valuation method. Compared to the current price of 12.12 USD, Entrada Therapeutics Inc is Overvalued By 70.39%.

What is Entrada Therapeutics Inc (TRDA) fair value?

TRDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Entrada Therapeutics Inc (TRDA) is between 1.78 to 7.11 according to relative valuation method.

How does TRDA's valuation metrics compare to the industry average?

The average P/S ratio for TRDA's competitors is 11.22, providing a benchmark for relative valuation. Entrada Therapeutics Inc Corp (TRDA) exhibits a P/S ratio of 22.83, which is 103.53% above the industry average. Given its robust revenue growth of -96.53%, this premium appears unsustainable.

What is the current P/B ratio for Entrada Therapeutics Inc (TRDA) as of Mar 04 2026?

As of Mar 04 2026, Entrada Therapeutics Inc (TRDA) has a P/B ratio of 1.06. This indicates that the market values TRDA at 1.06 times its book value.

What is the current FCF Yield for Entrada Therapeutics Inc (TRDA) as of Mar 04 2026?

As of Mar 04 2026, Entrada Therapeutics Inc (TRDA) has a FCF Yield of -36.01%. This means that for every dollar of Entrada Therapeutics Inc's market capitalization, the company generates -36.01 cents in free cash flow.

What is the current Forward P/E ratio for Entrada Therapeutics Inc (TRDA) as of Mar 04 2026?

As of Mar 04 2026, Entrada Therapeutics Inc (TRDA) has a Forward P/E ratio of -2.48. This means the market is willing to pay $-2.48 for every dollar of Entrada Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Entrada Therapeutics Inc (TRDA) as of Mar 04 2026?

As of Mar 04 2026, Entrada Therapeutics Inc (TRDA) has a Forward P/S ratio of 22.83. This means the market is valuing TRDA at $22.83 for every dollar of expected revenue over the next 12 months.

TRDA Valuation